Fresenius Medical Care AG & Co. KGaA

Report Publication Announcement • Jul 1, 2016

ESN European Conference

Frankfurt | July 1, 2016

Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. The Company has based these forward-looking statements on its views with respect to future events an financial performance. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forward-looking statements. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.

If not mentioned differently the term net income after minorities refers to the net income attributable to the shareholders of Fresenius Medical Care AG Co. KGaA independent of being the reported or the adjusted number. The term EMEA refers to the region Europe, Middle East and Africa. Amounts are in US-\$ if not mentioned otherwise.

Our company profile

Health care services Products

Care Coordination

Therapies & laboratory services for patients with chronic kidney failure

Businesses supporting dialysis, e.g. vascular services

Dialysis services Dialysis products

e.g., dialysis machines, dialyzers & bloodline systems

\$11.5bn 69%* \$1.9bn 11%* \$3.3bn 20%*

* in % of 2015 revenue

AGENDA

Value-based care

Long-term targets

3

2

1

Dialysis services worldwide: Patients treated^{1 1} as of December 31, 2015, based on company statements and own estimates. North America EMEA Latin America Asia-Pacific USD ~73bn Market We lead in every major market, treating > 290,000 patients worldwide 23,000 180,600 182,852 U.S. Renal Care DaVita FMC 18,800 22,400 54,857 KfD Diaverum FMC 4,500 8,000 30,200 Diaverum Baxter FMC 5,100 5,200 26,472 B. Braun Showai-Kai FMC

Market position by major product groups 2015

	Position 1
Dialyzers	FMC
Dialysis machines	FMC
Hemodialysis concentrates	FMC
Bloodlines	FMC
Peritoneal dialysis products	Baxter

Patients, treatments, clinics – our global footprint

FY 2015	Patients	Treatments (mn)	Clinics
North America	182,852	27.7	2,210
EMEA	54,857	8.2	659
Asia-Pacific	26,472	3.8	320
Latin America	30,200	4.9	229
Total	294,381	44.6	3,418

AGENDA

*…our target is to have 30% of Medicare payment tied to quality or value through alternative payment models by the end of 2016 and 50% of payments by the end of 2018…

Key assets to deliver coordinated care

The Key to success

• National provider network Geography
• Diversified participation in value-based care
• Experience & expertise Care navigation Evidence-based protocols Research
• Process design
• Data analytics
• Technology & Skills
• Investments

AGENDA

• We will continue to grow our dialysis services and products business.
• We plan to further expand our Care Coordination activities.

ESN European Conference

Frankfurt | July 1, 2016